These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11312005)

  • 1. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani.
    Paraguai de Souza E; Bernardo RR; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2001 Apr; 19(23-24):3104-15. PubMed ID: 11312005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FML (Fucose Mannose Ligand) of Leishmania donovani. a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar.
    Palatnik de Sousa CB; Gomes EM; de Souza EP; dos Santos WR; de Macedo SR; de Medeiros LV; Luz K
    Rev Soc Bras Med Trop; 1996; 29(2):153-63. PubMed ID: 8713607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S; Smith DF; Kaye PM
    J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).
    Borja-Cabrera GP; Correia Pontes NN; da Silva VO; Paraguai de Souza E; Santos WR; Gomes EM; Luz KG; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2002 Sep; 20(27-28):3277-84. PubMed ID: 12213397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.
    Santos WR; Aguiar IA; Paraguai de Souza E; de Lima VM; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2003 Dec; 21(32):4668-76. PubMed ID: 14585674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P; Paik D; Naskar K; Chakraborti T
    Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani.
    Santos WR; Paraguai de Souza E; Palatnik M; Palatnik de Sousa CB
    Vaccine; 1999 Jun; 17(20-21):2554-61. PubMed ID: 10418902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
    Mukherjee M; Bhattacharyya A; Duttagupta S
    Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
    Bhowmick S; Mazumdar T; Sinha R; Ali N
    J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes.
    Afrin F; Anam K; Ali N
    J Parasitol; 2000 Aug; 86(4):730-5. PubMed ID: 10958448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani.
    Santos WR; Bernardo RR; Peçanha LM; Palatnik M; Parente JP; Palatnik de Sousa CB
    Vaccine; 1997 Jun; 15(9):1024-9. PubMed ID: 9261952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice.
    Afrin F; Rajesh R; Anam K; Gopinath M; Pal S; Ali N
    Infect Immun; 2002 Dec; 70(12):6697-706. PubMed ID: 12438344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
    Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis.
    Santos WR; de Lima VM; de Souza EP; Bernardo RR; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2002 Nov; 21(1-2):30-43. PubMed ID: 12443660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections.
    Ghosh A; Zhang WW; Matlashewski G
    Vaccine; 2001 Oct; 20(1-2):59-66. PubMed ID: 11567746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T; Anam K; Ali N
    Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.